Jw Pharmac (001060) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Jw Pharmac stock KRW 49,292, price KRW 22,600, upside +118.1%, quality 71 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 15,210 KRW – 44,704 KRW · fair‑value band 31,778 KRW – 66,922 KRW · the 22,600 KRW price screens below the 49,292 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Jw Pharmac in your weekly email
Every Wednesday you see whether Jw Pharmac is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer.
Show moreShow less
The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.
Stock analysis
Jw Pharmac (001060) currently trades at 22,600 KRW, while our model-based Fair Value estimate is 49,292 KRW, implying the stock looks roughly 54% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 60,430 KRW per share, and 20 of the 26 models we run sit above the 22,600 KRW price.
Bear case: the Dividend Discount group reads lowest at 5,823 KRW, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 31,778 KRW (bear) to 66,922 KRW (bull), the price of 22,600 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Jw Pharmac reported revenue of 775B KRW in FY2025 versus 607B KRW in FY2021, a compound +6.3%/yr. Reported net income was 61.5B KRW in FY2025.
Key figures
Market cap 510B KRW (≈ $377M) Small · P/E ratio 10.1 · P/S ratio 0.80 · EPS (TTM) 2,201 KRW · Dividend yield 2.9% · Net margin 7.9% · Return on equity 27.6% · Return on assets (EBIT) 12.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 118%, 001060 screens cheaper than that median.
Fair Value models
Bear31,778 KRWFair Value 49,292 KRWBull66,922 KRW
Price 22,600 KRW · Upside +118.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1,330 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2020 (pandemic). Over 10 years: +6.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +17.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.6%
Dividend (yield on the price)2.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 12%
⚠ Rate on operating basis: 2025 sits 71% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −3.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 14/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+118.1% · Top 25%
Profitability
Return on equity (12 months)27.6% · Top 25%
Return on assets10.2% · Top 25%
Net margin (12 months)12.3% · Above median
Operating margin (12 months)15.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)16.2% · Above median
Dividend yield (12 months)2.9% · Above median
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jw Pharmac Fair Value". https://www.fairvalue-calculator.com/stock/001060
Frequently asked questions
Is Jw Pharmac (001060) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 49,292 KRW versus a price of 22,600 KRW, about +118% upside (undervalued).
What is the fair value of 001060?
Our model-based fair value for Jw Pharmac is 49,292 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 22,600 KRW.
What is the quality score of 001060?
Jw Pharmac has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Pharmac (001060)?
Our model-based price target is the fair value of 49,292 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 31,778 KRW, optimistic scenario 66,922 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Pharmac stock forecast for 2026?
Our models put fair value at 49,292 KRW, about +118% upside versus a price of 22,600 KRW (undervalued). Cautious scenario 31,778 KRW, optimistic scenario 66,922 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Pharmac (001060)?
Jw Pharmac reported trailing-twelve-month revenue of about 821B KRW (latest available figure, as of Nov 8, 2026).
Does Jw Pharmac pay a dividend?
Jw Pharmac currently shows a dividend yield of 2.88% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Jw Pharmac (001060) and when is the ex-dividend date?
Jw Pharmac pays a dividend of 650.00 KRW per share a year, a dividend yield of 2.9%. The last ex-dividend date was Mar 31, 2026. The payout ratio is 29.5% of earnings. Free cash flow covers the dividend 4.11 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Jw Pharmac (001060)?
For today's price to be fair in a discounted-cash-flow model, Jw Pharmac would have to grow free cash flow by -1.5 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.2 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 001060 use?
Our models discount Jw Pharmac at 11.7 %: a base by market capitalisation (small), damped by beta 1.02, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jw Pharmac that is -1.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has Jw Pharmac (001060) delivered so far?
Over the past 5 years revenue at Jw Pharmac grew +7.2 % a year. The price currently implies free-cash-flow growth of -1.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jw Pharmac (001060) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Jw Pharmac (-1.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jw Pharmac (001060)?
The free-cash-flow yield on the price is 11.83 %: that much free cash flow Jw Pharmac produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jw Pharmac (001060)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Pharmac it is 49,292 KRW per share (as of Nov 8, 2026), against a price of 22,600 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Jw Pharmac stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 001060 trades below its calculated fair value: price 22,600 KRW, fair value 49,292 KRW, a gap of about +118% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 001060?
No. The price is what the market pays today (22,600 KRW); the fair value is what the company's own numbers justify (49,292 KRW). For Jw Pharmac the two are 26,692 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Pharmac worth?
The market values Jw Pharmac at about 510B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 22,600 KRW; our models calculate a fair value of 49,292 KRW per share.
What do the bullish and bearish scenarios say about 001060?
Our models span a range for Jw Pharmac: cautious scenario 31,778 KRW, base 49,292 KRW, optimistic 66,922 KRW per share (as of Nov 8, 2026, price 22,600 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 001060?
Jw Pharmac trades at a price-to-earnings ratio of 10.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 49,292 KRW is built from several models across several years. Other multiples: P/B 1.4, P/S 0.6, EV/EBITDA 3.9.
How solid is the balance sheet of Jw Pharmac (001060)?
Balance-sheet figures for Jw Pharmac (as of Nov 8, 2026): return on equity 27.6%, debt of 0.07 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 001060 from its 52-week high?
Jw Pharmac trades at 22,600 KRW, about 41% below its 52-week high of 38,234 KRW and at the low of 22,600 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 49,292 KRW is for.
Which stocks are comparable to Jw Pharmac?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Pharmac stock attractive at the current price?
The data as of Nov 8, 2026: price 22,600 KRW, calculated fair value 49,292 KRW (+118%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 001060 calculated?
We run Jw Pharmac through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 49,292 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Jw Pharmac currently trades 54% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Pharmac (001060)?
The closing price on Nov 6, 2026 was 22,600 KRW. Our model-based fair value is 49,292 KRW, about +118% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Pharmac right now?
The price is below even our cautious bear case (31,778 KRW). The market is more pessimistic than our downside scenario. Solid quality (71/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (31,778 KRW to 66,922 KRW) leaves room in how you read the outcome.
Key figures of Jw Pharmac
How large is the market capitalisation of Jw Pharmac (001060)?
The market capitalisation of Jw Pharmac is 510B KRW (≈ $377M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Pharmac (001060)?
The price-to-sales ratio of Jw Pharmac is 0.80 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jw Pharmac (001060)?
Earnings per share at Jw Pharmac are 2,201 KRW (price ÷ EPS = P/E 10.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jw Pharmac (001060)?
The dividend yield of Jw Pharmac is 2.9% (payout 29.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jw Pharmac (001060)?
The net margin of Jw Pharmac is 7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jw Pharmac (001060)?
The return on equity (ROE) of Jw Pharmac is 27.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Pharmac (001060)?
On an EBIT basis the return on assets of Jw Pharmac is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Pharmac (001060)?
The operating margin of Jw Pharmac is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Pharmac (001060)?
Revenue at Jw Pharmac is growing +16.2% versus a year earlier (3y avg +4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jw Pharmac (001060)?
Earnings per share at Jw Pharmac are growing +59.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jw Pharmac (001060) carry?
The net debt of Jw Pharmac is 56.1B KRW (fiscal year 2024, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jw Pharmac in the live analysis
One click puts Jw Pharmac on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026